Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $98.
Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $98.